Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology derived from an invention by clinicians from Stanford University. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France. For more information, please visit: www.gradientdenervation.com
Medical Devices
Anne joined Sofinnova Partners in 2019 after having been Venture Partner for several years. She has been the CEO of SafeHeal (MD Start II’s first company) for 2 years, and is currently transitioning out of the company to focus on being the CEO of Ablacare (MD Start II’s third company). Upon closing of ...
© 2020 Sofinnova Partners TERMS AND CONDITIONS